Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

RASILEZ HCT DIN 02332736

Status: Cancelled Post Market
Holder: NODEN PHARMA DAC
Molecule: ALISKIREN (ALISKIREN FUMARATE)

Health Canada record

Active ingredient(s)ALISKIREN (ALISKIREN FUMARATE) 150 MG; HYDROCHLOROTHIAZIDE 25 MG
Dosage formTablet
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCC09XA52 ALISKIREN AND HYDROCHLOROTHIAZIDE
Original market date24-Nov-2009
Current status date11-Feb-2020
SourceHealth Canada DPD

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing ALISKIREN (ALISKIREN FUMARATE)

DINProductCompanyFormStrengthStatus
02302063RASILEZNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 150 MGCancelled Post Market
02302071RASILEZNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 300 MGCancelled Post Market
02332728RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 150 MG; HYDROCHLOROTHIAZIDE 12.5 MGCancelled Post Market
02332744RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 300 MG; HYDROCHLOROTHIAZIDE 12.5 MGCancelled Post Market
02332752RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 300 MG; HYDROCHLOROTHIAZIDE 25 MGCancelled Post Market
02441896SANDOZ ALISKIRENSANDOZ CANADA INCORPORATEDTabletALISKIREN (ALISKIREN FUMARATE) 150 MGCancelled Pre Market
02441918SANDOZ ALISKIRENSANDOZ CANADA INCORPORATEDTabletALISKIREN (ALISKIREN FUMARATE) 300 MGCancelled Pre Market

Notices of Compliance

NOCDateSubmissionReason
203662018-01-17New Drug Submission (NDS)MERGER - BUYOUT
105732009-09-04New Drug Submission (NDS)
Request a quote for RASILEZ HCT

How to read a Canadian DIN record